EBV BZLF1 (190-197) (TFA)

EBV BZLF1 (190-197) TFA is an immunodominant CEF-controlling peptide derived from Epstein-Barr virus (EBV) . EBV BZLF1 (190-197) TFA is a suitable epitope for CD8+ T cells to stimulate the release of IFNg. CTL responses to EBV BZLF1 (190-197) TFA are diverse and cross-recognize similar peptides from both host self-proteins and bacterial proteins. EBV BZLF1 (190-197) TFA can be used to study autoimmune diseases[1].

12352209

Bacterial

Anti-infection

COVID-19-anti-virus

Infection; Inflammation/Immunology

98.74

O=C(N[C@@H](C)C(N[C@@H](CCCCN)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](CCCCN)C(N[C@@H](CCC(N)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(O)=O)=O)=O)=O)=O)=O)=O)[C@H](CCCNC(N)=N)N.OC(C(F)(F)F)=O.[x]

C47H82N14O10.xC2HF3O2

1003.24 (free base)

[1]Misko IS, et al. Crossreactive recognition of viral, self, and bacterial peptide ligands by human class I-restricted cytotoxic T lymphocyte clonotypes: implications for molecular mimicry in autoimmune disease. Proc Natl Acad Sci U S A. 1999 Mar 2;96 (5) :2279-84.

Blue Ice

-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

http://file.medchemexpress.com/batch_PDF/HY-P10497A/EBV-BZLF1-190-197-TFA-SDS-MedChemExpress.pdf

Peptides

No Development Reported